Proposal for a Simple Algorithmic Approach to Manage Drug-Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients Comment

被引：5
|
作者：
Rizk, John G. [1 ]
Lazo, Jose G., Jr. [2 ]
Gupta, Aashish [3 ]
Lavie, Carl J. [3 ]
Effron, Mark B. [3 ]
机构：
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA
[2] Univ Calif San Francisco, UCSF Med Ctr, Dept Pharm, San Francisco, CA 94143 USA
[3] Univ Queensland, Sch Med, Ochsner Clin Sch, John Ochsner Heart & Vasc Inst,Dept Cardiol, New Orleans, LA USA
来源：
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2023年 / 49卷 / 01期
关键词：
PROTEASE INHIBITOR RITONAVIR;
D O I：
10.1055/s-0042-1750024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 88
页数：4
相关论文
共 50 条
  • [1] Nirmatrelvir/ritonavir drug-drug interactions in primary care outpatients
    Esquiroz, Andrea Rodriguez
    Alvarez, Lorea Sanz
    Marin, Marta Marin
    Gonzalez, Patricia Garcia
    Cobos, Paula Aldave
    Parra, Javier Garjon
    ANALES DEL SISTEMA SANITARIO DE NAVARRA, 2023, 46 (03)
  • [2] Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
    Vazquez, Sara R.
    Wilson, Aaron S.
    Witt, Daniel M.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2022, 54 (04) : 583 - 586
  • [3] MANAGEMENT OF POTENTIAL DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR-RITONAVIR AND ORAL ANTICOAGULANTS: A CASE SERIES
    Wilson, Aaron S.
    Vazquez, Sara R.
    Witt, Daniel M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E120 - E120
  • [4] Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
    Sara R. Vazquez
    Aaron S. Wilson
    Daniel M. Witt
    Journal of Thrombosis and Thrombolysis, 2022, 54 : 583 - 586
  • [5] Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions
    Marzolini, Catia
    Kuritzkes, Daniel R.
    Marra, Fiona
    Boyle, Alison
    Gibbons, Sara
    Flexner, Charles
    Pozniak, Anton
    Boffito, Marta
    Waters, Laura
    Burger, David
    Back, David
    Khoo, Saye
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (05) : 744 - +
  • [6] Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
    Marzolini, Catia
    Kuritzkes, Daniel R.
    Marra, Fiona
    Boyle, Alison
    Gibbons, Sara
    Flexner, Charles
    Pozniak, Anton
    Boffito, Marta
    Waters, Laura
    Burger, David
    Back, David J.
    Khoo, Saye
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1191 - 1200
  • [7] A CASE OF CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTIONS OF PAXLOVID (NIRMATRELVIR/RITONAVIR) WITH CONCURRENT MEDICATIONS IN THE MANAGEMENT OF COVID-19
    Weill, Sydney
    Reddy, Anisha
    Bugos, Eva
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 : S370 - S370
  • [8] Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients
    Cordero, Carlos Guzman
    de Vicente, Maria Saez-Torres
    Espinosa, Alvaro Jimenez
    Sanchez, Ana Isabel Gago
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [9] Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions
    Shen, Dan
    Gong, Yinhua
    Qian, Yulan
    Zhu, Jianguo
    Gao, Jie
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2024, 52 (05)
  • [10] Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
    Girardin, Francois
    Manuel, Oriol
    Marzolini, Catia
    Buclin, Thierry
    CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (08) : 1044 - 1046
12345